Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma-Which is best?

Lung Cancer

Volumn 74, Issue 1, 2011, Pages 55-60

  Creaney, Jenette ^a,b   Yeoman, Deborah ^a   Musk, Arthur William ^a,b,c   de Klerk, Nicholas ^a,d   Skates, Steven J ^a,e   Robinson, Bruce W S ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Mesothelin; Mesothelioma; Osteopontin; SMRP; Tumor markers; Wittenoom

Indexed keywords

BIOLOGICAL MARKER; MESOTHELIN; OSTEOPONTIN;

ARTICLE; ASBESTOSIS; BLOOD LEVEL; BLOOD SAMPLING; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; PLEURA DISEASE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYMPTOM;

ADULT; AGED; AGED, 80 AND OVER; BLOOD SPECIMEN COLLECTION; FEMALE; GPI-LINKED PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; OSTEOPONTIN; PLASMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SERUM; TUMOR MARKERS, BIOLOGICAL;

EID: 80052605129     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.02.007     Document Type: Article

References (35)

1. Robinson B.W., Lake R.A. Advances in malignant mesothelioma. N Engl J Med 2005, 353:1591-1603.
2. Robinson B.W., Musk A.W., Lake R.A. Malignant mesothelioma. Lancet 2005, 366:397-408.
3. Creaney J., Robinson B.W. Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med 2009, 15:366-370.
4. Chang K., Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996, 93:136-140.
5. Scholler N., Fu N., Yang Y., Ye Z., Goodman G.E., Hellstrom K.E., et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 1999, 96:11531-11536.
6. Zhou W., Sokoll L.J., Bruzek D.J., Zhang L., Velculescu V.E., Goldin S.B., et al. Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers Prev 1998, 7:109-112.
7. Hellstrom I., Raycraft J., Kanan S., Sardesai N.Y., Verch T., Yang Y., et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006, 15:1014-1020.
8. Ho M., Onda M., Wang Q.C., Hassan R., Pastan I., Lively M.O. Mesothelin is shed from tumor cells. Cancer Epidemiol Biomarkers Prev 2006, 15:1751.
9. Robinson B.W., Creaney J., Lake R., Nowak A., Musk A.W., de Klerk N., et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003, 362:1612-1616.
10. Scherpereel A., Grigoriu B.D., Conti M., Gey T., Gregoire M., Copin M.C., et al. Soluble mesothelin-related protein in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006.
11. Grigoriu B.D., Scherpereel A., Devos P., Chahine B., Letourneux M., Lebailly P., et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007, 13:2928-2935.
12. Cristaudo A., Foddis R., Vivaldi A., Guglielmi G., Dipalma N., Filiberti R., et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007, 13:5076-5081.
13. Creaney J., van Bruggen I., Hof M., Segal A., Musk A.W., de Klerk N., et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007.
14. Hassan R., Remaley A.T., Sampson M.L., Zhang J., Cox D.D., Pingpank J., et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006, 12:447-453.
15. Creaney J., Olsen N.J., Brims F., Dick I.M., Musk A.W., de Klerk N.H., Skates S.J., Robinson B.W. Serum mesothelin for early detection of the asbestos-induced cancer maligant mesothelioma. Cancer Epidemiol Biomarkers Prev. 2010, 19:2238-2246.
16. Rittling S.R., Chambers A.F. Role of osteopontin in tumour progression. Br J Cancer 2004, 90:1877-1881.
17. Pass H.I., Lott D., Lonardo F., Harbut M., Liu Z., Tang N., et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005, 353:1564-1573.
18. Creaney J., Yeoman D., Demelker Y., Segal A., Musk A.W., Skates S.J., et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008, 3:851-857.
19. Mack P.C., Redman M.W., Chansky K., Williamson S.K., Farneth N.C., Lara P.N., et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 2008, 26:4771-4776.
20. Isa S., Kawaguchi T., Teramukai S., Minato K., Ohsaki Y., Shibata K., et al. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol 2009, 4:1104-1110.
21. Bramwell V.H., Doig G.S., Tuck A.B., Wilson S.M., Tonkin K.S., Tomiak A., et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 2006, 12:3337-3343.
22. Martinetti A., Bajetta E., Ferrari L., Zilembo N., Seregni E., Del Vecchio M., et al. Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. Endocr Relat Cancer 2004, 11:771-779.
23. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
24. Henderson D.W., Shilkin K.B., Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 1998, 110:397-404.
25. Husain A.N., Colby T.V., Ordonez N.G., Krausz T., Borczuk A., Cagle P.T., et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009, 133:1317-1331.
26. Whitaker D. The cytology of malignant mesothelioma. Cytopathology 2000, 11:139-151.
27. Scherpereel A., Lee Y.C.G. Biomarkers for mesothelioma. Curr Opin Pulm Med 2007, 13:339-443.
28. Roe O.D., Creaney J., Lundgren S., Larsson E., Sandeck H., Boffetta P., et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer 2008, 61:235-243.
29. Park E.K., Sandrini A., Yates D.H., Creaney J., Robinson B.W., Thomas P.S., et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med 2008, 178:832-837.
30. Park E.K., Thomas P.S., Johnson A.R., Yates D.H. Osteopontin levels in an asbestos-exposed population. Clin Cancer Res 2009, 15:1362-1366.
31. Wai P.Y., Kuo P.C. The role of osteopontin in tumor metastasis. J Surg Res 2004, 121:228-241.
32. Johnston N.I., Gunasekharan V.K., Ravindranath A., O'Connell C., Johnston P.G., El-Tanani M.K. Osteopontin as a target for cancer therapy. Front Biosci 2008, 13:4361-4372.
33. Kadota J., Mizunoe S., Mito K., Mukae H., Yoshioka S., Kawakami K., et al. High plasma concentrations of osteopontin in patients with interstitial pneumonia. Respir Med 2005, 99:111-117.
34. Ohmori R., Momiyama Y., Taniguchi H., Takahashi R., Kusuhara M., Nakamura H., et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003, 170:333-337.
35. Creaney J., van Bruggen I., Hof M., Segal A., Musk A.W., de Klerk N., et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007, 132:1239-1246.